Boehringer Ingelheim Launches “Conoce a Don Francisco” Sweepstakes

RIDGEFIELD, CT – May 19, 2016 – Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is launching the “Conoce a Don Francisco” sweepstakes, offering a chance to meet iconic entertainer Mario Kreutzberger (better known as Don Francisco), who for the past two years has been the face of the company’s “Cuida Tu Don” initiative. Aimed at engaging and educating Hispanics with type 2 diabetes, which Don Francisco is affected by, Cuida Tu Don provides resources for treatment options and tips for long-term healthy lifestyle choices.

The Conoce a Don Francisco sweepstakes prize includes round-trip airfare for two to Miami, hotel accommodations, and transportation to-and-from a private dinner with Don Francisco. Entries can be submitted by visiting www.ConoceADonFrancisco.com.

“We are proud of our partnership with Don Francisco to engage and educate the millions of Hispanics in the U.S. living with type 2 diabetes Cuida Tu Don has focused on,” said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs – Metabolism at Boehringer Ingelheim. “Our new sweepstakes offers fans the chance to meet Don Francisco in person, providing another way for him to inspire others to face the challenges that come with living with type 2 diabetes."

“Type 2 diabetes is part of my life, and I’ve experienced first-hand that by staying informed I can still do everything I love and live life to the fullest,” said Mario Kreutzberger. “I’m excited to have the opportunity to meet the winner face to face.”

In order to join the conversation about the sweepstakes, friends and family can share their stories on social media using #ConoceADonFrancisco. The winner will be chosen by June 16, 2016, and the trip will take place between June 27 and July 1, 2016. 

For official sweepstakes rules, terms and conditions and to enter the Conoce a Don Francisco sweepstakes, please visit www.ConoceADonFrancisco.com. For helpful tips and resources in Spanish about type 2 diabetes, please visit www.CuidaTuDon.com, and always remember to speak to your healthcare provider about any questions or concerns you may have.  

About Diabetes
Approximately 29 million Americans and an estimated 415 million people worldwide have type 1 or type 2 diabetes, and nearly 28 percent of Americans with diabetes—totaling 8 million people—are undiagnosed. In the U.S., approximately 12 percent of those aged 20 and older have diabetes. T2D is the most common type, accounting for an estimated 90 to 95 percent of all diagnosed adult diabetes cases in the U.S. Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with 145 affiliates and more than 47,000 employees. Since its founding in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel treatments for human and veterinary medicine.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families.  Our employees create and engage in programs that strengthen our communities. To learn more about how we make more health for more people, visit our Corporate Social Responsibility Report.

In 2015, Boehringer Ingelheim achieved net sales of about $15.8 billion (14.8 billion euros). R&D expenditure corresponds to 20.3 percent of its net sales.

For more information please visit www.us.boehringer-ingelheim.com, or follow us on Twitter @BoehringerUS.